These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6288240)

  • 61. [Clinical aspects and chemotherapy of adenocarcinoma of the kidney].
    Possinger K; Hartenstein R; Ehrhart H
    Fortschr Med; 1981 Mar; 99(12):419-23. PubMed ID: 7227939
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparisons of Cooperative Group evaluation criteria for multiple-drug therapy for breast cancer.
    Davis HL; Multhauf P; Klotz J
    Cancer Treat Rep; 1980; 64(2-3):507-17. PubMed ID: 7407792
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Current status of chemotherapy, hormonal therapy, and immunotherapy in the treatment of renal cell carcinoma.
    Poster DS; Bruno S; Penta JS; Pinna K; Vilk P; Macdonald JS
    Am J Clin Oncol; 1982 Feb; 5(1):53-60. PubMed ID: 7081138
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Pulmonary metastasis of renal cell carcinoma].
    Satomi Y
    Gan No Rinsho; 1983 May; 29(6):555-60. PubMed ID: 6876423
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment of renal carcinoma: a phase III randomized trial of oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine.
    Stolbach LL; Begg CB; Hall T; Horton J
    Cancer Treat Rep; 1981; 65(7-8):689-92. PubMed ID: 6454485
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase II study of spirogermanium in advanced adenocarcinoma of the prostate: a Southwest Oncology Group Study.
    Saiers JH; Blumenstein B; Slavik M; Costanzi JH; Crawford ED
    Cancer Treat Rep; 1987 Dec; 71(12):1305-6. PubMed ID: 3690546
    [No Abstract]   [Full Text] [Related]  

  • 67. [On the medical treatment of metastases of hypernephroid cancer of the kidneys].
    Evseenko LS; Orlova RS; Barsel' VA; Disvetova VV
    Vopr Onkol; 1966; 12(9):53-5. PubMed ID: 6004069
    [No Abstract]   [Full Text] [Related]  

  • 68. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma.
    Schneider RJ; Woodcock TM; Yagoda A
    Cancer Treat Rep; 1980 Jan; 64(1):183-5. PubMed ID: 6892892
    [No Abstract]   [Full Text] [Related]  

  • 69. Third-line chemotherapy with mitomycin, vinblastine, and carmustine (BCNU) in refractory breast carcinoma: a pilot study.
    Veronesi A; Tirelli U; Galligioni E; Trovò MG; Crivellari D; Donatella Magri M; Roncadin M; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Mar; 66(3):559-61. PubMed ID: 7060044
    [No Abstract]   [Full Text] [Related]  

  • 70. [Prospects of systemic drug treatment in metastasized bladder and kidney tumors].
    Hartlapp JH; Illiger HJ
    MMW Munch Med Wochenschr; 1983 Mar; 125(9):172-5. PubMed ID: 6405255
    [No Abstract]   [Full Text] [Related]  

  • 71. [Ovarian adenocarcinoma stage III and IV treated by a combination of adriamycin, cyclophosphamide, 5-fluorouracil and cis-DDP. Therapeutic role of cis-DDP in this combination].
    Pouillart P; Bretaudeau B; Palangie T; Jouve M; Garcia-Giralt E; Asselain B
    Bull Cancer; 1982; 69(5):434-42. PubMed ID: 6891903
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
    Chang YC; Falkson G; Tormey DC; Crowley J
    Cancer Clin Trials; 1981; 4(4):377-80. PubMed ID: 6797746
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase II study of 3-deazauridine in advanced colorectal adenocarcinoma.
    Bruno S; Creaven PJ; Ledesma E; Poster D; Yoon J; Mittelman A
    Am J Clin Oncol; 1982 Feb; 5(1):69-71. PubMed ID: 7081140
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phase II Study of AMSA, prednisone, and chlorambucil (APC) in the treatment of refractory breast cancer: a Northern California Oncology Group Study.
    Friedman MA; Marcus F; Kohler M; Resser KJ
    Cancer Treat Rep; 1982 May; 66(5):1235-6. PubMed ID: 7083225
    [No Abstract]   [Full Text] [Related]  

  • 75. Prognosis of metastatic renal adenocarcinoma.
    Nurmi M; Nikkanen TA
    Strahlentherapie; 1984 Jul; 160(7):411-5. PubMed ID: 6464044
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phase II study of oral medroxyprogesterone acetate in advanced germ cell tumors.
    Cavalli F; Klepp O; Hansen H; Rozencweig M
    Cancer Treat Rep; 1983 Oct; 67(10):953-4. PubMed ID: 6313188
    [No Abstract]   [Full Text] [Related]  

  • 77. Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II.
    Ruckdeschel JC; Mehta CR; Salazar OM; Cohen M; Vogl S; Koons LS; Lerner H
    Cancer Treat Rep; 1981; 65(11-12):965-72. PubMed ID: 7028258
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of advanced renal cell carcinoma--traditional methods and innovative approaches.
    deKernion JB
    J Urol; 1983 Jul; 130(1):2-7. PubMed ID: 6191048
    [No Abstract]   [Full Text] [Related]  

  • 79. [Usefulness of medroxyprogesterone acetate in the co-adjuvant treatment of renal carcinoma in advanced stages].
    Morote J; de Torres JA
    Med Clin (Barc); 1987 Feb; 88(7):301-2. PubMed ID: 3561080
    [No Abstract]   [Full Text] [Related]  

  • 80. [Treatment of metastatic renal cancer in adults with elliptinium acetate].
    Amiel JL; Rouessé J; Droz JP; Caille P; Travagli JP; Théodore C; Le Chevalier T; Ducret JP; Bidart M; Garnier HS
    Presse Med; 1984 Jun; 13(25):1555-7. PubMed ID: 6234539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.